Legis Daily

Maintaining Investments in New Innovation Act

USA118th CongressHR-5547| House 
| Updated: 12/17/2024
Wiley Nickel

Wiley Nickel

Democratic Representative

North Carolina

Cosponsors (28)
Diana Harshbarger (Republican)Michael C. Burgess (Republican)Adrian Smith (Republican)Rick W. Allen (Republican)Neal P. Dunn (Republican)Mike Carey (Republican)Claudia Tenney (Republican)Mariannette Miller-Meeks (Republican)Beth Van Duyne (Republican)Scott H. Peters (Democratic)Donald G. Davis (Democratic)Ken Calvert (Republican)Lloyd Smucker (Republican)A. Drew Ferguson (Republican)Sheila Cherfilus-McCormick (Democratic)Daniel Meuser (Republican)Joseph D. Morelle (Democratic)Mike Kelly (Republican)Richard Hudson (Republican)John Joyce (Republican)Blake D. Moore (Republican)August Pfluger (Republican)Larry Bucshon (Republican)Dan Crenshaw (Republican)Kevin Hern (Republican)Josh Gottheimer (Democratic)Nicole Malliotakis (Republican)Vern Buchanan (Republican)

Ways and Means Committee, Health Subcommittee, Health Subcommittee, Energy and Commerce Committee

  • Introduced
  • In Committee
  • On Floor
  • Passed Chamber
  • Enacted
Maintaining Investments in New Innovation Act This bill requires drug products with genetically targeted technology to have had market approval for at least 11 years in order to qualify for the Medicare Drug Price Negotiation Program. (The program requires the Centers for Medicare & Medicaid Services to negotiate the prices of certain prescription drugs under Medicare beginning in 2026. Among other requirements, drugs must have had market approval for at least 7 years (for drug products) or 11 years (for biologics) to qualify for negotiation.)
View Full Text

Suggested Questions

Get AI-generated questions to help you understand this bill better

Timeline
Feb 16, 2023

Latest Companion Bill Action

S 118-476
Introduced in Senate
Sep 18, 2023
Introduced in House
Sep 18, 2023
Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
Sep 22, 2023
Referred to the Subcommittee on Health.
Dec 17, 2024
Referred to the Subcommittee on Health.
  • February 16, 2023

    Latest Companion Bill Action

    S 118-476
    Introduced in Senate


  • September 18, 2023
    Introduced in House


  • September 18, 2023
    Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.


  • September 22, 2023
    Referred to the Subcommittee on Health.


  • December 17, 2024
    Referred to the Subcommittee on Health.

Health

Related Bills

  • S 118-476: Maintaining Investments in New Innovation Act
GeneticsMedicarePrescription drugs

Maintaining Investments in New Innovation Act

USA118th CongressHR-5547| House 
| Updated: 12/17/2024
Maintaining Investments in New Innovation Act This bill requires drug products with genetically targeted technology to have had market approval for at least 11 years in order to qualify for the Medicare Drug Price Negotiation Program. (The program requires the Centers for Medicare & Medicaid Services to negotiate the prices of certain prescription drugs under Medicare beginning in 2026. Among other requirements, drugs must have had market approval for at least 7 years (for drug products) or 11 years (for biologics) to qualify for negotiation.)
View Full Text

Suggested Questions

Get AI-generated questions to help you understand this bill better

Timeline
Feb 16, 2023

Latest Companion Bill Action

S 118-476
Introduced in Senate
Sep 18, 2023
Introduced in House
Sep 18, 2023
Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
Sep 22, 2023
Referred to the Subcommittee on Health.
Dec 17, 2024
Referred to the Subcommittee on Health.
  • February 16, 2023

    Latest Companion Bill Action

    S 118-476
    Introduced in Senate


  • September 18, 2023
    Introduced in House


  • September 18, 2023
    Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.


  • September 22, 2023
    Referred to the Subcommittee on Health.


  • December 17, 2024
    Referred to the Subcommittee on Health.
Wiley Nickel

Wiley Nickel

Democratic Representative

North Carolina

Cosponsors (28)
Diana Harshbarger (Republican)Michael C. Burgess (Republican)Adrian Smith (Republican)Rick W. Allen (Republican)Neal P. Dunn (Republican)Mike Carey (Republican)Claudia Tenney (Republican)Mariannette Miller-Meeks (Republican)Beth Van Duyne (Republican)Scott H. Peters (Democratic)Donald G. Davis (Democratic)Ken Calvert (Republican)Lloyd Smucker (Republican)A. Drew Ferguson (Republican)Sheila Cherfilus-McCormick (Democratic)Daniel Meuser (Republican)Joseph D. Morelle (Democratic)Mike Kelly (Republican)Richard Hudson (Republican)John Joyce (Republican)Blake D. Moore (Republican)August Pfluger (Republican)Larry Bucshon (Republican)Dan Crenshaw (Republican)Kevin Hern (Republican)Josh Gottheimer (Democratic)Nicole Malliotakis (Republican)Vern Buchanan (Republican)

Ways and Means Committee, Health Subcommittee, Health Subcommittee, Energy and Commerce Committee

Health

Related Bills

  • S 118-476: Maintaining Investments in New Innovation Act
  • Introduced
  • In Committee
  • On Floor
  • Passed Chamber
  • Enacted
GeneticsMedicarePrescription drugs